The International Cardio-Oncology Society (ICOS) has designated Winship Cancer Institute of Emory University a gold-level Cardio-Oncology “Center of Excellence,” one of fewer than 35 gold-level centers worldwide. The gold-level designation is the highest status awarded by ICOS and follows a rigorous application process and review by an international certification committee.
Anant Mandawat, MD, director of Winship’s Cardio-Oncology Program, says ICOS’s Center of Excellence designation is significant for Winship and its patients. “It highlights Winship’s focus on comprehensive and integrative care,” he says, “in particular, our strong track record of collaborative and personalized cardiac care for patients with cancer.”
ICOS defines a Cardio-Oncology Center of Excellence as a program with a high concentration of expertise that is providing care in a comprehensive, interdisciplinary fashion. ICOS notes that cardiovascular side effects are common among people treated for cancer. Some cardiac diseases predate the cancer diagnosis, while other conditions — such as chemotherapy-induced cardiomyopathy, immune checkpoint inhibitor myocarditis and radiation-related heart disease — are directly related to the cardiotoxic side effects of some cancer therapies. Importantly, cardiovascular toxicity can interrupt or limit cancer treatment, resulting in worse outcomes.
Congrats to the Winship Cardio-Oncology Program on this significant recognition!
Be the first to comment on "Winship named among world’s top Cardio-Oncology Centers of Excellence!"